Alluvi, previously BI 4744, represents a promising development in obesity treatment. This dual agonist targeting both glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptors demonstrates https://bookmarkjourney.com/story22125733/alluvi-a-detailed-dive-into-retatrutide-s-potential